New target for prostate cancer therapy

(Medical Xpress) -- Researchers at Imperial College London have discovered a molecule that plays an important role in driving prostate cancer growth, and could be a target for new therapies.

About 36,000 men are diagnosed with each year in the UK, making it the most common cancer in men. The cancer depends on male hormones to progress, as these hormones stimulate the to divide, enabling the to grow.

The new study, published in , found that increase the production of a molecule called miR-27a in prostate cancer cells in the laboratory, and that this molecule stimulates the cells to grow. An inhibitor of miR-27a halved the growth rate of , suggesting that such a molecule might have therapeutic potential.

miR-27a belongs to a class of molecules called microRNAs – short strands of genetic material which are increasingly understood to play an important role in regulating gene activity. MicroRNAs are appealing as therapeutic targets since compared with proteins, it is much easier to design and synthesise inhibitory that can get into cells easily. Another microRNA inhibitor is already being tested in humans in combination with chemotherapy for prostate cancer.

“This is a promising first step towards a possible new therapy, but there are many hurdles to overcome first,” said Claire Fletcher, the study’s first author, who is studying for a PhD in Dr Charlotte Bevan’s lab in the Department of Surgery and Cancer at Imperial.

“MicroRNAs have only been known about for the last 10 years, but we’re now realising how important they are in regulating which genetic messages are read and thus which proteins are produced. This study shows that miR-27a is an important intermediary that links hormones with prostate . We’ve demonstrated that inhibiting this molecule can suppress prostate cancer growth in the lab. The next step is to test that concept in an animal model. It will be several years at least before we can test any new treatments in humans.”

The subset of genes that are turned on in a cell determine how the cell behaves. If a gene is switched on, its code is copied onto a messenger molecule and the message is translated to make a protein, which carries out a specific function. MicroRNAs work by interfering with the messenger so that the protein does not get made.

Each microRNA can regulate many genes. The new study found that one of the targets of miR-27a is a tumour suppressor called prohibitin, which the Imperial team previously discovered is a regulator of prostate cancer growth.

The research was funded by the Medical Research Council, Cancer Research UK and Prostate Cancer UK.

More information: CE Fletcher et al. ‘Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer.’ Human Molecular Genetics (2012) 21 (14):3112-3127.doi: 10.1093/hmg/dds139

Related Stories

Prostate cancer early warning protein detected

May 31, 2012

(Medical Xpress) -- Scientists at the University have discovered a protein, only present in prostate cancer cells, that could be used as a marker to detect early signs of the disease.     

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

23 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.